Ligand‐targeted drug delivery (LTDD) has emerged as an attractive option in the field of oligonucleotide drugs following the great success of N‐acetylgalactosamine (GalNAc)–conjugated siRNA and antisense oligonucleotides. GalNAc is a… Click to show full abstract
Ligand‐targeted drug delivery (LTDD) has emerged as an attractive option in the field of oligonucleotide drugs following the great success of N‐acetylgalactosamine (GalNAc)–conjugated siRNA and antisense oligonucleotides. GalNAc is a well‐known ligand of the asialoglycoprotein receptor (ASGPR), and is classified as a C‐type lectin associated with the metabolism of desialylated glycoproteins. This article describes the synthesis of a non‐nucleosidic monovalent GalNAc phosphoramidite—a useful reagent for facilitating the conjugation of GalNAc epitopes into oligonucleotides using DNA synthesizers—together with some important caveats. The monomeric GalNAc consists of three parts: (1) a GalNAc moiety, (2) a linker moiety, and (3) a trans‐4‐hydroxyprolinol (tHP) branch point. The GalNAc moiety and the tHP moiety are coupled via a condensation reaction to prepare the monovalent GalNAc phosphoramidite. © 2019 by John Wiley & Sons, Inc.
               
Click one of the above tabs to view related content.